DOCSLIB.ORG

Year-End Reports

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Year-End Reports Pharmaceutical Training Seminar – 2016 Year-End Reports UN Reporting and Quota Section [email protected] (202) 307-7184 Pre-YERS History Ø ARCOS system was developed to track the distribution of controlled substances. Manufacturer >> Distributor >> Various Retail Outlets Ø Timeliness of registrants completing reports makes it less suitable for certain DEA functions. It was decided that ARCOS data could not be used to comply with UN mandates YERS History Ø In the early 90’s, the DEA created year- end reports to facilitate: l Establishment & Revision of • Aggregate Production Quotas (APQ) – CI, CII • Assessment of Annual Needs (AAN) – List 1 • I ndividual registrant quotas (IQ,MQ,PQ) l Monitoring the “80/20” NRM import rule l UN-treaty mandated reporting Year-end Reporting Benefits Ø Provides secure web-based database system Ø Preloads your available drug codes, historical data Ø Performs calculations Ø Generates error messages for possible incorrect entries or when “specify” fields are not completed Ø Moves submitted reports to completed list Year-end Reporting Reports need to be completed by: l DEA REGISTERED MANUFACTURERS l Schedule I and II controlled substances l Psychotropic drugs on UN’s “green list” l DEA REGISTERED LIST 1 IMPORTERS l Ephedrine l Pseudoephedrine l Phenylpropanolamine Please Note Ø Due by January 31 after end of reporting CY Ø Separate report required for each substance if l Quota was issued for that reporting CY l Inventory processed or carried over from an earlier CY l Psychotropic drug on UN’s ‘green list’ l Newly scheduled CI or CII drugs Ø Quantities reported should expressed as: l Anhydrous acid, base or alkaloid l GRAMS Accessing YERS Online www.deadiversion.usdoj.gov Reporting Year-End Reports YERS Online New Accounts: complete Secure website user agreement, print, sign, & email to ODE Quota to receive corporate administrator log-in Enter DEA issued user name & password Corporate Administrator Login Create New Corporate User Account Corporate User Login Corporate User Login Confirmation Report Selection Menu Report Selection Year-end Reporting UN mandated individual reports for the following optical isomers: l Amphetamine • d-amphetamine • l-amphetamine • d,l-amphetamine l Methamphetamine • d-methamphetamine • l-methamphetamine • d,l-methamphetamine l Tetrahydrocannabinols • Delta-9-THC • All Other Tetrahydrocannabinols “For Sale” vs. “For Conversion” l Codeine l D-Amphetamine l D-Methamphetamine l Diphenoxylate l Hydrocodone l Morphine l Noroxymorphone l Oxycodone l Oxymorphone “For Sale” vs. “For Conversion” For Sale: substance used to manufacture products containing same basic class which is bought from the bulk manufacturer. - involves ~95% of the quota applications ex: Codeine (for sale) codeine/APAP For Conversion: substance used to synthesize a different basic class. ex: Codeine (for conversion) hydrocodone Report Selection Confirmation Year-end Reporting: Inventory Ø Inventories include amounts held by the registrant under manufacturer, importer, exporter or distributor registrations at that physical location Ø “Bulk Controlled Substance” is the amount of raw material in inventory Ø “In-process” - i.e. beads not yet encapsulated Ø “Non-saleable Materials” includes any non-saleable inventory - i.e. retains, product development, pending destructions Inventory Year-end Reporting: Acquisitions Ø Only material which was obtained against a quota should be reported under “Domestic Procurement” or “Manufactured/ Produced/ Synthesized/ Extracted” Ø Material acquired through authorized replacement of destroyed material is reported under “Other Acquisitions to be Accounted For” Acquisitions Year-end Reporting: Dispositions Ø Material acquired with current year’s quota Ø Material from previous year’s inventory • Domestic sales / transfers • Exempted products • Exports • Returns • Authorized destructions Dispositions Summary Totals Confirmation Completed Reports Year End Report Manufacturing Selection Menu Year-end Reporting Ø Narcotic Raw Materials reporting is required by 1961 Single Convention on Narcotic Drugs: l Opium l Concentrated poppy straw (CPS) Ø Alkaloids in CPS which are reported: l Codeine l Morphine l Oripavine l Thebaine Year-end Report for Bulk Manufacturers Ø To be completed by a manufacturer who manufactures, produces, synthesizes or extracts a bulk Schedule I or II controlled substance Ø In-process inventories are to be reported as end-product inventories, not as precursor inventories l based on actual assay of in-process material, or l based on historical yields Conversion Reporting Ø To be completed by a manufacturer who utilized a basic class for conversion to another controlled or non- controlled substance l Example 1 - If a manufacturer used phenylacetone to synthesize amphetamine, the amount of phenylacetone used and the amount of amphetamine synthesized would be reported on this worksheet l Example 2 - Manufacturer received a “codeine (for conversion)” manufacturing quota and utilized it for purposes of making “hydrocodone (for sale)”. Ø This is NOT to be used to report: l the manufacture of dosage forms l the manufacture of exempt or excluded products l the “conversion” of a basic class to a different schedule (i.e. II to a III, IV or V) Dispositions – Bulk Conversions Dispositions– Bulk Conversions Summary Summary Totals Confirmation Year End Report Procurement Selection Menu UN Psychotropic Substance Report Ø Specified psychotropic substances in UN Schedules III and IV, member countries voluntarily submit statistics to UN l Check the DEA Diversion web site (www.deadiversion.usdoj.gov) l Check the INCB web site (www.incb.org) l Check the “green list” - attached Ø Bulk and non-bulk manufacturers should report. Ø DEA attempted to codify a regulation which would have required such reporting (circa 1992), however never promulgated the rule. Year End Report Psychotropic Selection Menu Psychotropic Substances to be Reported 71 Schedule III: Ø Clotiazepam Ø Meprobamate Ø Mesocarb Ø Cloxazolaml Ø Methylphenobarbital Ø Buprenorphine Ø Delorazepam Ø Methyprylon Ø Butalbital Ø Ø Diazepam Midazolam Ø Cathine Ø Nimetazepam Ø Ø Cyclobarbital Diethylpropion Ø Nitrazepam Ø Flunitrazepam Ø Estazolam Ø Nordazepam Ø Pentazocine Ø Ethchlorvynol Ø Oxazepam Ø Ethinamate Ø Oxazolam 71 Schedule IV: Ø Ethyl loflazepate Ø Pemoline Ø Fencamfamin Ø Phendimetrazine Ø Allobarbital Ø Fenproporex Ø Phenobarbital Ø Ø Alprazolam Ø Fludiazepam Phentermine Ø Pinazepam Ø Barbital Ø Flurazepam Ø Pipradrol Ø Benzphetamine Ø Halazepam Ø Prazepam Ø Bromazepam Ø Haloxazolam Ø Ø Pyrovalerone Brotizolam Ø Ketazolam Ø Camazepam Ø Secbutabarbital Ø Loprazolam Ø Chlordiazepoxide Ø SPA (lefetamine) Ø Lorazepam Ø Clobazam Ø Temazepam Ø Lormetazepam Ø Clonazepam Ø Tetrazepam Ø Mazindol Ø Clorazepate Ø Triazolam Ø Medazepam Ø Vinylbital Ø Mefenorex Ø Zolpidem Psychotropic Report Questions? UN Reporting and Quota Section [email protected] (202) 307-7184 .
Load more

Recommended publications
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Smumedical Journal
    SMU Medical Journal ISSN : 2349 – 1604 (Volume – 4, No. 1, January 2017) Review Article Indexed in SIS (USA), ASI (Germany), I2OR & i-Scholar (India), SJIF (Morocco) and Cosmos Foundation (Germany) databases. Impact Factor: 3.835 (SJIF) Analytical Aspects with Brief Overview of Depressants Sandeep Kumar1 Nand Gopal Giri2 Ashok Kumar Jaiswal3* Anil Kumar Jaiswal4 1M.Sc. (Forensic Science), LNJN NICFS, New Delhi 110085, 2Assistant Professor, Department of Chemistry, Shivaji College (University of Delhi) Raja Garden, New Delhi 110 027, 3Dept. of Forensic Medicine and toxicology, All India institute of Medical Sciences, New Delhi 110 029.4Assistant Professor, Department of Mathematics, St. Andrew’s PG College, Gorakhpur, UP. *Corresponding author Manuscript received : 30.10.2016 Manuscript accepted: 21.11.2016 Abstract Depressants are drugs that slow down the functions of the central nervous system (CNS). These drugs are used to reduce anxiety and insomnia without drowsiness. The depressants cause relaxed feeling if used in small quantity but cause unconsciousness, vomiting and even death if taken in high quantity. It affects concentration and coordination of a person by slowing down his/ her ability to respond in unexpected situations. These drugs are also attributed for their physiological and psychological effects, eventually in large dose it become lethal. The different 142 SMU Medical Journal, Volume – 4, No. – 1, January, 2017 physical and chemical features of some very often used depressants are discussed in this manuscript. Keyword: Depressant, TLC, UV spectroscopy, HPLC, GLC etc. Introduction The classical depressants are hypnotics (which induce sleep), most antianxiety medicine (diazepam or valium), muscle spasm prevent seizure, but these drugs rapidly develop dependence and tolerance which finally leads to coma and death, so use of these drugs is highly unsafe.
    [Show full text]
  • EUROPEAN COMMISSION Strasbourg
    EUROPEAN COMMISSION Strasbourg, 11.3.2014 COM(2014) 166 final ANNEX 1 – PART 4/11 ANNEX to the Proposal for a Regulation of the European Parliament and of the Council on the reduction or elimination of customs duties on goods originating in Ukraine EN EN Tariff schedules of EU CN 2008 DESCRIPTION Base rate Staging category II. ALCOHOLS AND THEIR HALOGENATED, SULPHONATED, NITRATED OR NITROSATED DERIVATIVES 2905 Acyclic alcohols and their halogenated, sulphonated, nitrated or nitrosated derivatives - Saturated monohydric alcohols 2905 11 00 -- Methanol (methyl alcohol) 5,5 0 2905 12 00 -- Propan-1-ol (propyl alcohol) and propan-2-ol (isopropyl alcohol) 5,5 0 2905 13 00 -- Butan-1-ol (n-butyl alcohol) 5,5 0 2905 14 -- Other butanols 2905 14 10 --- 2-Methylpropan-2-ol (tert-butyl alcohol) 4,6 0 2905 14 90 --- Other 5,5 0 2905 16 -- Octanol (octyl alcohol) and isomers thereof 2905 16 10 --- 2-Ethylhexan-1-ol 5,5 0 2905 16 20 --- Octan-2-ol Free 0 2905 16 80 --- Other 5,5 0 2905 17 00 -- Dodecan-1-ol (lauryl alcohol), hexadecan-1-ol (cetyl alcohol) and octadecan-1-ol (stearyl alcohol) 5,5 0 2905 19 00 -- Other 5,5 0 - Unsaturated monohydric alcohols EU/UA/Annex I-A/en 286 CN 2008 DESCRIPTION Base rate Staging category 2905 22 -- Acyclic terpene alcohols 2905 22 10 --- Geraniol, citronellol, linalol, rhodinol and nerol 5,5 0 2905 22 90 --- Other 5,5 0 2905 29 -- Other 2905 29 10 --- Allyl alcohol 5,5 0 2905 29 90 --- Other 5,5 0 - Diols 2905 31 00 -- Ethylene glycol (ethanediol) 5,5 0 2905 32 00 -- Propylene glycol (propane-1,2-diol) 5,5 0 2905
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Korea Industrial Tariff Schedule
    DRAFT Subject to Legal Review for Accuracy, Clarity, and Consistency Annex 2-B Industrial Schedule for the Republic of Korea Staging HSK 10 Description Base Rate Category 0301101000 Gold carp 10 C 0301102000 Tropical fish 10 C 0301109000 Other 10 A 0301911000 Salmo trutta, Oncorhynchus mykiss,Oncorhynchus clarki, Oncorhynchus 10 C aguabonita,Oncorhynchus gilae 0301912000 Oncorhynchus apache and Oncorhynchus chrysogaster 10 C 0301921000 Glass eel 10 A 0301929000 Other 30% or I ￦1,908/kg 0301930000 Carp 10 C 0301992000 Yellow tail 10 A 0301994000 Sea-bream 45% or G ￦3,292/kg 0301995000 Conger eel 10 G 0301996000 Sharp toothed eel 10 G 0301997000 Salad eel 10 C 0301998000 Flat fish 10 C 0301999010 True bass 10 G 0301999020 Puffers 10 G 0301999030 Tilapia 10 C 0301999040 Rock fish(including pacific ocean perch) 10 C 0301999050 Sea bass 40 C 0301999060 Mullets 10 C 0301999070 Loaches 10 C 0301999080 Cat fishes 10 A 0301999091 Rock Trout(Hexagrammos spp., Agrammus spp.) 10 C 0301999092 Crusian carp 10 C 0301999093 Salmon 10 A 0301999094 Grass carp 10 A 0301999095 Croakers 36 G 0301999099 Other 10 G 0302111000 Salmo trutta, Oncorhynchus mykiss, Oncorhynchus clarki,Oncorhynchus 20 G aquabonita, Oncorhynchus gilae 0302112000 Oncorhynchus apache and Oncorhynchus chrysogaster 20 A 0302120000 Pacific salmon(Oncorhynchus nerka, Oncorhynchus gorbuscha, Oncorhynchus 20 A keta, Oncorhynchus tschawytscha, Oncorhynchus kisutch, Oncorhynchus masou and Oncorhynchus rhodurus), Atlantic salmon(Salmo salar)and Danube salmon(Hucho hucho) 0302190000 Other 20
    [Show full text]
  • JCE0997 P1122 Separation of Enantiomeric Barbiturates By
    In the Laboratory Separation of Enantiomeric Barbiturates by Capillary Electrophoresis Using a Cyclodextrin-Containing Run Buffer S. Conradi and C. Vogt* Institute of Analytical Chemistry, University of Leipzig, Linnéstr. 3, 04103 Leipzig, Germany E. Rohde Department of Chemistry, University of Cincinnati, Mail Location 172, Cincinnati, OH 45221 In the last few years capillary electrophoresis (CE) has The easy handling of the instrumentation and the fast been successfully applied to a variety of analytical problems and inexpensive method optimization even for challenging (1, 2). Especially in the field of chiral separations CE has problems such as chiral analysis make the application of been useful in many cases. The experiment described here CE in general and the utilization of the described experi- serves as an introduction to chiral separations by CE. The ment in an advanced undergraduate/graduate laboratory separation of enantiomers (R/S) is based on the addition of course very attractive. a suitable chiral selector to the buffer. Native or derivatized cyclodextrins perform as excellent selectors and have there- Experimental Procedure fore been used widely (3). These molecules themselves are chiral. They are applied as enantiomeric pure substances Instrumentation and can form complexes with the chiral analyte. The com- The instrument used in this work was a Beckman cap- pounds formed are then chemically distinguishable diaste- illary electrophoresis model P/ACE 2100. It was equipped reomers. Complex formation depends on parameters such as with a detector which has a set of fixed wavelengths in the pH, the structure of the selector and the analyte, and the UV region. Absorbance was monitored at 200 and 254 nm concentration of the selector.
    [Show full text]
  • 201 PART 329—HABIT-FORMING DRUGS Subpart A—Derivatives
    Food and Drug Administration, HHS § 329.1 section 502(e) of the Federal Food, PART 329ÐHABIT-FORMING DRUGS Drug, and Cosmetic Act. (d) The statement expressing the Subpart AÐDerivatives Designated as amount (percentage) of alcohol present Habit Forming in the product shall be in a size reason- ably related to the most prominent Sec. printed matter on the panel or label on 329.1 Habit-forming drugs which are chem- which it appears, and shall be in lines ical derivatives of substances specified in generally parallel to the base on which section 502(d) of the Federal Food, Drug, the package rests as it is designed to be and Cosmetic Act. displayed. (e) For a product to state in its label- Subpart BÐLabeling ing that it is ``alcohol free,'' it must 329.10 Labeling requirements for habit- contain no alcohol (0 percent). forming drugs. (f) For any OTC drug product in- tended for oral ingestion containing Subpart CÐExemptions over 5 percent alcohol and labeled for use by adults and children 12 years of 329.20 Exemption of certain habit-forming age and over, the labeling shall contain drugs from prescription requirements. the following statement in the direc- AUTHORITY: 21 U.S.C. 352, 353, 355, 371. tions section: ``Consult a physician for use in children under 12 years of age.'' SOURCE: 39 FR 11736, Mar. 29, 1974, unless (g) For any OTC drug product in- otherwise noted. tended for oral ingestion containing over 0.5 percent alcohol and labeled for Subpart AÐDerivatives use by children ages 6 to under 12 years Designated as Habit Forming of age, the labeling shall contain the following statement in the directions § 329.1 Habit-forming drugs which are section: ``Consult a physician for use in chemical derivatives of substances children under 6 years of age.'' specified in section 502(d) of the (h) When the direction regarding age Federal Food, Drug, and Cosmetic in paragraph (e) or (f) of this section Act.
    [Show full text]
  • Uniform Classification Guidelines for Foreign Substances, Version 7.00
    Association of Racing Commissioners International, Inc. Drug Testing Standards and Practices Program Model Rules Guidelines Uniform Classification Guidelines for Foreign Substances and Recommended Penalties and Model Rule Version 7.00 Revised January 2014 Association of Racing Commissioners International, Inc. Uniform Classification Guidelines for Foreign Substances Table of Contents Preamble to the Uniform Classification Guidelines of Foreign Substances ..................................................................................... ii Notes Regarding Classification Guidelines ...................................................................................................................................... ii Classification Criteria ....................................................................................................................................................................... iii Classification Definitions ................................................................................................................................................................. iv Drug Classification Scheme ............................................................................................................................................................. vi Alphabetical Substance List ............................................................................................................................................................... 1 Listing by Classification ..................................................................................................................................................................
    [Show full text]
  • High Resolution and High Precision Analysis of Barbiturates and a Metabolite in Human Body Fluids Using a Monolithic Spin Tip and UPLC-Q-Tof-MS
    Showa Univ J Med Sci 30（2）, 175～187, June 2018 Original High Resolution and High Precision Analysis of Barbiturates and a Metabolite in Human Body Fluids Using a Monolithic Spin Tip and UPLC-Q-ToF-MS 1 1 2 1 Yukiko SHOUJI ）, Chika HASEGAWA＊ ，）, Xiao-Pen LEE＊ ）, 1 1 1 Masaya FUJISHIRO ）, Takaaki MATSUYAMA ）, Miho YAMADA ）, 3 1 1 Ayako KURIKI ）, Yuka KATO ）, Noriko NEMOTO ）, 1 4 1 5 1 Takeshi KUMAZAWA ，）, Shinichi SUZUKI ，） and Keizo SATO ） Abstract : A high-throughput method was developed to analyze five barbiturates （phenobarbital, cyclobarbital, amobarbital, secobarbital, and thiopental） and a metabo- lite in human body samples using a new Monolithic C18 gel-packed Spin Tip and ultra-performance liquid chromatography （UPLC）-quadrupole-time-of-flight （Q-ToF） mass spectrometry （MS）. Plasma （20 µl） or urine （100 µl） samples spiked with the five barbiturates and 5-（4-methylphenyl）-5-phenylhydantoin （internal standard, IS） were mixed with distilled water. The mixture was extracted using the Monolithic C18 Spin Tip, and the analytes retained on the C18 phase were then eluted with metha- nol. The eluate was injected directly into an analytical column （Waters Acquity BEH C18, 50 mm × 2.1 mm i.d., particle size 1.7 µm）, and quantified by Q-ToF-MS with negative-ion electrospray ionization （ESI）. Good separation and clear peak shapes of the ve drugs were achieved within an analysis time of 6 min, including the extraction time. All drugs spiked in the plasma showed recoveries of 86-98％. The regression equations for the ve drugs showed excellent linearities in the range of 5-500 ng/20 µl of plasma, with limits of detection and i-Fit of 1 ng/20 µl.
    [Show full text]
  • Korea Tariff Schedule
    Annex 2-B Tariff Schedule of Korea HSK Description Base rate Staging Category Safeguard 0101101000 Horses 8 D 0101109000 Other 8 D 0101901010 Horses for racing 8 D 0101901090 Other 8 D 0101909000 Other 8 G 0102101000 Milch cows 89.1 A 0102102000 Beef cattle 89.1 A 0102109000 Other 89.1 A 0102901000 Milch cows 40 M 0102902000 Beef cattle 40 H 0102909000 Other 0 K 0103100000 1. Pure-bred breeding animals 18 A 0103910000 Weighing less than 50kg 18 G 0103920000 Weighing 50kg or more 18 G 0104100000 Sheep 8 A 0104201000 Milch goats 8 G 0104209000 Other 8 A 0105111000 Pure-bred breeding animals 9 A 0105119000 Other 9 A 0105120000 B. Turkeys 9 A 0105191000 Ducks 18 G 0105199000 Other 9 A 0105921000 (1) Pure-bred breeding animals 9 A 0105929000 (2)Other 9 A 0105931000 (1) Pure-bred breeding animals 9 A 0105939000 (2) Other 9 A 0105991000 Ducks 18 G 0105992000 Turkeys 9 A 0105999000 Other 9 A 0106110000 Primates 8 A Whales, dolphins and porpoises(mammals 0106120000 of the order Cetacea); manatees and 8A dugongs(mammals of the order Sirenia) 0106191000 Dogs 8 D 0106192000 Rabbits and hares 8 D 0106193000 Deer 8 G 0106194000 Bears 8 A 0106199000 Other 8 D 0106201000 Snakes 8 A 0106202000 Fresh-water tortoises 8 D 0106203000 Turtles 8 A 0106209000 Other 8 A 0106310000 Birds of prey 8 D Psittaciformes (including parrots, 0106320000 8D parakeets, macaws and cockatoos) 0106390000 Other 8 A 0106901000 Amphibia 8 A 0106902010 Honey bees 8 D 0106902090 Other 8 A 0106903010 Lug worms 8 A 0106903020 Yarn earth worms 8 A 0106903090 Other 8 A 0106909000 Other
    [Show full text]
  • THE NATIONAL CONGRESS DECREES: Chapter I General Rules
    LAW NO. 1008 OF 19 JULY 1988 ON THE REGIME APPLICABLE TO COCA AND CONTROLLED SUBSTANCES Whereas the National Congress has ratified the following Law: THE NATIONAL CONGRESS DECREES: TITLE I THE REGIME APPLICABLE TO COCA Chapter I General rules, nature and definitions Article 1 . Coca, which belongs to the genus erythroxylon, is a natural subtropical product of the Departments of La Paz and Cochabamba. It grows wild and is also cultivated, and dates back to the pre-Columbian period of Bolivian history. Article 2. Coca-growing is an agricultural and cultural activity that has been traditionally oriented in a legitimate manner towards consumption and to use in medicine and in rituals of the Andean peoples. Article 3. For legal purposes, an essential difference is made between coca in its natural state, which does not produce harmful effects on human health, and coca " iter criminis", that is to say, the leaf in the process of chemical transformation, isolating the alkaloid cocaine, which produces harmful psychological, physiological and biological effects on human health. Article 4. Legal consumption and use of the coca leaf are understood to mean the social and cultural practices of the Bolivian people in traditional forms, such as acullicu and chewing and medicinal and ritual uses. Article 5. Other forms of legal use of the coca leaf that do not harm health or lead to any type of drug dependence or addiction, as well as industrial processing for legal use, shall be subject to special regulation. Article 6. The production of coca leaf that covers demand for the uses and consumption referred to in articles 4 and 5 is defined as necessary production.
    [Show full text]
  • 210 PART 329—HABIT-FORMING DRUGS Subpart A
    § 329.1 21 CFR Ch. I (4±1±97 Edition) container label and that are not mar- (h) When the direction regarding age keted in another retail package (e.g., in paragraph (e) or (f) of this section an outer box), the statement of the per- differs from an age-limiting direction centage of alcohol present in the prod- contained in any OTC drug monograph uct shall appear prominently and con- in this chapter, the direction contain- spicuously on the ``principal display ing the more stringent age limitation panel'' of the immediate container shall be used. label. (c) For products whose principal dis- PART 329ÐHABIT-FORMING DRUGS play panel is on the retail package and the retail package is not the imme- Subpart AÐDerivatives Designated as diate container, the statement of the Habit Forming percentage of alcohol present in the product shall also appear on the imme- Sec. diate container label; it may appear 329.1 Habit-forming drugs which are chemi- anywhere on that label in accord with cal derivatives of substances specified in section 502(e) of the Federal Food, section 502(d) of the Federal Food, Drug, Drug, and Cosmetic Act. and Cosmetic Act. (d) The statement expressing the Subpart BÐLabeling amount (percentage) of alcohol present in the product shall be in a size reason- 329.10 Labeling requirements for habit- ably related to the most prominent forming drugs. printed matter on the panel or label on which it appears, and shall be in lines Subpart CÐExemptions generally parallel to the base on which 329.20 Exemption of certain habit-forming the package rests as it is designed to be drugs from prescription requirements.
    [Show full text]